全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Rationalizing Optimal Timing for Adjuvant Hormone Therapy for Patients with Breast Cancer: Impact on Limited Resource Countries

DOI: 10.4236/ijcm.2016.76044, PP. 419-432

Keywords: Optimization, Tamoxifen, Breast Cancer, Limited Resource Countries

Full-Text   Cite this paper   Add to My Lib

Abstract:

Modern day cancer chemotherapy is complex and involves multiple drugs given either sequentially or concurrently, as an adjuvant or neo-adjuvant. Besides the concentration of the drug, timing, duration and sequencing of individual drugs in combination with other similar agents play a vital role in the final therapeutic outcome. This study constitutes an exhaustive overview of current knowledge of timing and sequencing, specifically of Tamoxifen, based on tumor’s hormone receptor status, as part of a comprehensive treatment plan. It has become apparent that inappropriate timing or sequencing can be detrimental. On the other hand, appropriate timing and sequencing of Tamoxifen, based on breast cancer cell-biology, pharmacokinetics and pharmacodynamics of drugs, the body’s homeostatic response to drugs; surgery and radiation, yield huge benefit for locoregional control, long-term survival and reducing complications in patients with breast cancer. Conclusion: A rational plan for use of Tamoxifen has been recommended, based on this study; for optimal therapeutic benefit. It has also been suggested that in receptor “unknown cases”, it is beneficial to prescribe Tamoxifen, since 75% of breast cancers are likely to be estrogen receptor positive and side effects can be minimized with planned vigilance.

 References

[1]  Recht, A., Come, S.E., Gellman, R.S., Goldstein, M., Tishler, S., Gore, S.M., Abner, A.L., Vicini, F.A., Silver, B. and Connolly, J.L. (1991) Integration of Conservative Surgery, Radiotherapy, and Chemotherapy for the Treatment of Early-Stage, Node-Positive Breast Cancer: Sequencing, Timing, and Outcome. Journal of Clinical Oncology, 9, 1662-1667.
[2]  Gradishar, W. (2006) Landmark Trials in Endocrine Adjuvant Therapy for Breast Carcinoma. Cancer, 106, 975-981.
http://dx.doi.org/10.1002/cncr.21707
[3]  Baum, M., et al. (1988) Controlled Trial of Tamoxifen as a Single Adjuvant Agent in the Management of Early Breast Cancer. ‘Nolvadex’ Adjuvant Trial Organization. British Journal of Cancer, 57, 608-611.
http://dx.doi.org/10.1038/bjc.1988.138
[4]  Osborne, C.K., Boldt, D.H., Clark, G.M. and Trent, J.M. (1983) Effects of Tamoxifen on Human Breast Cancer Cell Cycle Kinetics: Accumulation of Cells in Early G1 Phase. Cancer Research, 43, 3583-3585.
[5]  Sutherland, R.L., Green, M.D., Hall, R.E., Reddel, R.R. and Taylor, I.W. (1983) Tamoxifen Induces Accumulation of MCF 7 Human Mammary Carcinoma Cells in the G0/G1 Phase of the Cell Cycle. European Journal of Cancer and Clinical Oncology, 19, 615-621.
http://dx.doi.org/10.1016/0277-5379(83)90177-3
[6]  Malaker, K., Gillies, J.M. and Meikle, A. (1981) Cytostatic Effect of Tamoxifen Causing G0/G1 Delay in Cycling Breast Cancer Cells, May Adversely Affect Therapeutic Benefit of Chemotherapy Agents. Manitoba Cancer Treatment Research Foundation (MCTRF) Annual Report, Radiation Oncology Section, Winnipeg, 201.
[7]  Doisneau-Sixou, S.F., Sergio, C.M., Carroll, J.S., Hui, R., Musgrove, E.A. and Sutherland, R.L. (2003) Estrogen and Antiestrogen Regulation of Cell Cycle Progression in Breast Cancer Cells. Endocrine Related Cancer, 10, 179-186.
http://dx.doi.org/10.1677/erc.0.0100179
[8]  Lippman, M.E. and Dickson, R.B. (2012) Regulatory Mechanisms in Breast Cancer. Advances in Cellular and Molecular Biology of Breast Cancer, 306-322.
[9]  Patterson, J., Furr, B., Wakeling, A. and Battersby, L. (1982) The Biology and Physiology of ‘Nolvadex’ (Tamoxifen) in Treatment of Breast Cancer. Breast Cancer Research and Treatment, 2, 363-374.
http://dx.doi.org/10.1007/BF01805878
[10]  Lykkesfeldt, A.E., Larsen, J.K., Christensen, I.J. and Briand, P. (1984) Effects of the Antioestrogen Tamoxifen on the Cell Cycle Kinetics of the Human Breast Cancer Cell Line, MCF-7. British Journal of Cancer, 49, 717-722.
http://dx.doi.org/10.1038/bjc.1984.113
[11]  St. Croix, B., Florenes, V.A., Rak, J.W., Flanagan, M., Bhattacharya, N., Slingerland, J.M. and Kerbel, R.S. (1996) Impact of the Cyclin-Dependent Kinase Inhibitor p27Kip1 on Resistance of Tumor Cells to Anticancer Agents. Nature Medicine, 2, 1204-1210.
http://dx.doi.org/10.1038/nm1196-1204
[12]  Hall, E.J. and Giaccia, A.J. (2012) Radiobiology for the Radiologist. 7th Edition, Lippincott Williams & Wilkins. Chemotherapeutic Agents from Perspective of Radiation Biologist, 449-475.
[13]  Lippman, M.E., Cassidy, J., Wesley, M. and Young, R.C. (1984) A Randomized Attempt to Increase the Efficacy of Cytotoxic Chemotherapy in Metastatic Breast Cancer by Hormonal Synchronization. Journal of Clinical Oncology, 2, 28-36.
[14]  Pritchard, K.I. (2008) Combining Endocrine Agents with Chemotherapy: Which Patients and What Sequence? Cancer, 112, 718-722.
http://dx.doi.org/10.1002/cncr.23189
[15]  Albain, K., Green, S. and Ravdin, P. (2002) Adjuvant Chemotherapy with Hormone Therapy for Primary Breast Cancer Should Be Sequential Instead of Concomitant: Initial Results from Intergroup Trial 0100 (SWOG-8814). Proceedings of American Society of Clinical Oncology, 21-37a.
[16]  Pico, C., Martin, M., Jara, C., Barnadas, A., Pelegri, A., Balil, A., Camps, C., Frau, A., Rodriquez-Lescure, A., Lopez-Vega, J.M., De La Haba, J., Tres, A., Alvarez, I., Alba, E., Arcusa, A., Oltra, A., Batista, N., Checa, T., Perez-Carrion, R. and Curto, J., GEICAM Group (2004) Epirubicin-Cyclophosphamide Adjuvant Chemotherapy plus Tamoxifen Administered Concurrently versus Sequentially: Randomized Phase III Trial in Postmenopausal Node-Positive Breast Cancer Patients. A GEICAM 9401 Study. Annals of Oncology, 15, 79-87.
http://dx.doi.org/10.1093/annonc/mdh016
[17]  Bedognetti, D., Sertoli, M.R., Pronzato, P., Del Mastro, L., Venturini, M., Taveggia, P., Zanardi, E., Siffredi, G., Pastorino, S., Queirolo, P., Gardin, G., Wang, E., Monzeglio, C., Boccardo, F. and Bruzzi, P. (2011) Concurrent versus Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. Journal of the National Cancer Institute, 103, 1529-1539.
http://dx.doi.org/10.1093/jnci/djr351
[18]  Del Mastro, L., Dozin, B., Aitini, E., Catzeddu, T., Baldini, E., Contu, A., Durando, A., Danese, S., Cavazzini, G., Canavese, G., Bruzzi, P., Pronzato, P. and Venturini, M., GONO-MIG Group (2008) Timing of Adjuvant Chemotherapy and Tamoxifen in Women with Breast Cancer: Findings from Two Consecutive Trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group. Annals of Oncology, 19, 299-307.
http://dx.doi.org/10.1093/annonc/mdm475
[19]  Sideras, K. (2010) Tamoxifen Timing in Postmenopausal Breast Cancer Patients. NAMS.
http://www.medscape.com/viewarticle/717750
[20]  Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of Chemotherapy and Hormone Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomized Trials. The Lancet, 365, 1687-1717.
http://dx.doi.org/10.1016/S0140-6736(05)66544-0
[21]  Hall, E.J. and Giaccia, A.J. (2012) Radiobiology for the Radi-ologist. Chapter 5. Fractionated Radiation and Dose-Rate Effect. 7th Edition, Lippincott Williams & Wilkins, Philadelphia, 67-101.
[22]  Yang, L., Yuan, X., Wang, J., Gu, C., Zhang, H., Yu, J. and Liu, F. (2015) Radiosensitization of Human Glioma Cells by Tamoxifen is Associated with the Inhibition of PKC-I Activity in Vitro. Oncology Letters, 10, 473-478.
[23]  Papavramidou, N., Papavramidis, T. and Demetriou, T. (2010) Ancient Greek and Greco-Roman Methods in Modern Surgical Treatment of Cancer. Annals of Surgical Oncology, 17, 665-667.
http://dx.doi.org/10.1245/s10434-009-0886-6
[24]  Harris, E.E., Christensen, V.J., Hwang, W.T., Fox, K. and Solin, L. (2005) Impact of Concurrent versus Sequential Tamoxifen with Radiation Therapy in Early-Stage Breast Cancer Patients Undergoing Breast Conservation Treatment. Journal of Clinical Oncology, 23, 11-16.
http://dx.doi.org/10.1200/JCO.2005.09.056
[25]  Azria, D., Pelegrin, A., Dubois, J.B., Mirimanoff, R.O. and Ozsahin, M. (2005) Radiation Therapy and Tamoxifen: Concurrent or Sequential? It’s No Longer the Question! Journal of Clinical Oncology, 23, 4239-4241.
http://dx.doi.org/10.1200/JCO.2004.00.8623
[26]  Azria, D., Gourgou, S., Sozzi, W.J., Zouhair, A., Mirimanoff, R.O., Kramar, A., Lemanski, C., Dubois, J.B., Romieu, G., Pelegrin, A. and Ozsahin, M. (2004) Concomitant Use of Tamoxifen with Radiotherapy Enhances Subcutaneous Breast Fibrosis in Hypersensitive Patients. British Journal of Cancer, 91, 1251-1260.
http://dx.doi.org/10.1038/sj.bjc.6602146
[27]  Whelan, T. and Levine, M. (2005) Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. Journal of Clinical Oncology, 23, 1-4.
http://dx.doi.org/10.1200/JCO.2005.08.955
[28]  Pierce, L.J., Hutchins, L.F., Green, S.R., Lew, D.L., Gralow, J.R., Livingston, R.B., Osborne, C.K. and Albain, K.S. (2005) Sequencing of Tamoxifen and Radiotherapy after Breast-Conserving Surgery in Early-Stage Breast Cancer. Journal of Clinical Oncology, 23, 24-29.
http://dx.doi.org/10.1200/JCO.2005.01.198
[29]  Ismail, S.S., Abdel-Hafeez, Z.M., EL Khodary, D.A.E. and Kelany, M.R. (2013) Trial of Concurrent versus Sequential Tamoxifen with Radiotherapy in Breast Cancer Patients with Study of the Combination of Pentoxifylline and Tocopherol for Prevention of Radiation-Induced Lung Fibrosis. Journal of Clinical Oncology, 31, e11599.
[30]  Bentzen, S.M., Skoczylas, J.Z., Overgaard, M. and Overgaard, J. (1996) Radiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen. Journal of the National Cancer Institute, 88, 918-922.
http://dx.doi.org/10.1093/jnci/88.13.918
[31]  Ishitobi, M., Komoike, Y., Motomura, K., Koyama, H., Nishiyama, K. and Inaji, H. (2009) Retrospective Analysis of Concurrent vs. Sequential Administration of Radiotherapy and Hormone Therapy Using Aromatase Inhibitor for Hormone Receptor-Positive Postmenopausal Breast Cancer. Anticancer Research, 29, 4791-4794.
[32]  Tsoutsou, P.G., Belkacemi, Y., Gligorov, J., Kuten, A., Boussen, H., Bese, N., Koukourakis, M.I. and on Behalf of Association of Radiotherapy and Oncology in the Mediterranean Area (2010) Optimal Sequence of Implied Modalities in the Adjuvant Setting of Breast Cancer Treatment: An Update on Issues to Consider. The Oncologist, 15, 1169-1178.
http://dx.doi.org/10.1634/theoncologist.2010-0187
[33]  Ahn, P.H., Vu, H.T., Lannin, D., Obedian, E., DiGiovanna, M.P., Burtness, B. and Haffty, B.G. (2005) Sequence of Radiotherapy with Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal of Clinical Oncology, 23, 17-23.
http://dx.doi.org/10.1200/JCO.2005.09.048
[34]  Koc, M., Polat, P. and Suma, S. (2002) Effect of Tamoxifen on Pulmonary Fibrosis after Cobalt-60 Radiotherapy in Breast Cancer Patients. Radiotherapy and Oncology, 64, 171-175.
http://dx.doi.org/10.1016/S0167-8140(02)00136-6
[35]  Cecchini, M.J., Yu, E., Potvin, K., D’souza, D. and Lock, M. (2015) Concurrent and Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review. Cureus, 7, e364.
http://dx.doi.org/10.7759/cureus.364
[36]  Munshi, A. and Gupta, D. (2011) Concurrent versus Sequential Radiotherapy and Tamoxifen in Breast Cancer—The CONSET Trial Is Launched. Acta Oncologica, 50, 154-155.
http://dx.doi.org/10.3109/0284186X.2010.504228
[37]  Demicheli, R., Retsky, M.W., Swartzendruber, D.E. and Bonadonna, G. (1997) Proposal for a New Model of Breast Cancer Metastatic Development. Annals of Oncology, 8, 1075-1080.
http://dx.doi.org/10.1023/A:1008263116022
[38]  Peeters, C.F.J.M., de Waal, R.M., Wobbes, T., Westphal, J.R. and Ruers, T.J. (2006) Outgrowth of Human Liver Metastases after Resection of the Primary Colorectal Tumor: A Shift in the Balance between Apoptosis and Proliferation. International Journal of Cancer, 119, 1249-1253.
http://dx.doi.org/10.1002/ijc.21928
[39]  Schatten, W.E. (1958) An Experimental Study of Postoperative Tumor Metastases. I. Growth of Pulmonary Metastases following Total Removal of Primary Leg Tumor. Cancer, 11, 455-459.
http://dx.doi.org/10.1002/1097-0142(195805/06)11:3<455::AID-CNCR2820110303>3.0.CO;2-3
[40]  Lange, P.H., Hekmat, K., Bosl, G., Kennedy, B.J. and Fraley, E. (1980) Accelerated Growth of Testicular Cancer after Cytoreductive Surgery. Cancer, 45, 1498-1506.
http://dx.doi.org/10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7
[41]  Demicheli, R., Retsky, M.W., Hrushesky, W., Baum, M. and Gukas, I.D. (2008) The Effects of Surgery on Tumor Growth: A Century of Investigations. Annals of Oncology, 19, 1821-1828.
http://dx.doi.org/10.1093/annonc/mdn386
[42]  Baum, M., Demicheli, R., Hrushesky, W. and Retsky, M. (2005) Does Surgery Unfavorably Perturb the “Natural History” of Early Breast Cancer by Accelerating the Appearance of Distant Metastases? European Journal of Cancer, 41, 508-515.
http://dx.doi.org/10.1016/j.ejca.2004.09.031
[43]  Lacy, A.M., Garcia-Valdecasas, J.C., Delgado, S., Castells, A., Taurá, P., Piquè, J.M. and Visa, J. (2002) Laparoscopy-Assisted Colectomy versus Open Colectomy for Treatment of Non-Metastatic Colon Cancer: A Randomized Trial. The Lancet, 359, 2224-2229.
http://dx.doi.org/10.1016/S0140-6736(02)09290-5
[44]  Mitsudomi, T., Nishioksa, K., Maruyama, R., Saitoh, G., Hamat ake, M., Fukuyama, Y., Yaita, H., Ishida, T. and Sugimachi, K. (1996) Kinetic Analysis of Recurrence and Survival after Potentially Curative Resection of Nonsmall Cell Lung Cancer. Journal of Surgical Oncology, 63, 159-165.
http://dx.doi.org/10.1002/(SICI)1096-9098(199611)63:3<159::AID-JSO5>3.0.CO;2-C
[45]  Gunduz, N., Fisher, B. and Saffer, E.A. (1979) Effect of Surgical Removal on the Growth and Kinetics of Residual Tumor. Cancer Research, 39, 3861-3865.
[46]  Fisher, B., Gunduz, N. and Saffer, E.A. (1983) Influence of the Interval between Primary Tumor Removal and Chemotherapy on Kinetics and Growth of Metastases. Cancer Research, 43, 1488-1492.
[47]  Maniwa, Y., Okada, M., Ishii, N. and Kyiooka, K. (1998) Vascular Endothelial Growth Factor Increased by Pulmonary Surgery Accelerates the Growth of Micrometastases in Metastatic Lung Cancer. Chest, 114, 1668-1675.
http://dx.doi.org/10.1378/chest.114.6.1668
[48]  Ikeda, M., Furukawa, H., Imamura, H., Shimizu, J., Ishida, H., Masutani, S., Tatsuta, M., Kawasaki, T. and Satomi, T. (2002) Surgery for Gastric Cancer Increases Plasma Levels of Vascular Endothelial Growth Factor and von Willebrand Factor. Gastric Cancer, 5, 137-141.
http://dx.doi.org/10.1007/s101200200024
[49]  Tagliabue, E., Agresti, R., Carcangiu, M.L., Ghirelli, C., Morelli, D., Campiglio, M., Martel, M., Giovanazzi, R., Greco, M., Balsari, A. and Ménard, S. (2003) Role of HER2 in Wound-Induced Breast Carcinoma Proliferation. The Lancet, 362, 527-533.
http://dx.doi.org/10.1016/S0140-6736(03)14112-8
[50]  Wu, F.P., Hoekman, K., Meijer, S. and Cuesta, M.A. (2003) VEGF and Endostatin Levels in Wound Fluid and Plasma after Breast Surgery. Angiogenesis, 6, 255-257.
http://dx.doi.org/10.1023/B:AGEN.0000029410.32264.b0
[51]  Maffini, M.V., Soto, A.M., Calabro, J.M., Ucci, A.A. and Sonnenschien, C. (2004) The Stroma as a Crucial Target in Rat Mammary Gland Carcinogenesis. Journal of Cell Science, 117, 1495-1502.
http://dx.doi.org/10.1242/jcs.01000
[52]  Maffini, M.V., Calabro, J.M., Soto, A.M. and Sonnenschien, C. (2005) Stromal Regulation of Neoplastic Development. Age-Dependent Normalization of Neoplastic Mammary Cells by Mammary Stroma. The American Journal of Patholology, 167, 1405-1410.
http://dx.doi.org/10.1016/S0002-9440(10)61227-8
[53]  Butta, A., MacLennan, K., Flanders, K.C., Sacks, N.P., Smith, I., McKinna, A., Dowsett, M., Wakefield, L.M., Sporn, M.B., Baum, M. and Colletta, A. (1992) Induction of Transforming Growth Factor Beta 1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment. Cancer Research, 52, 4261-4264.
[54]  Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A. and Jordan, V.C. (1991) Metabolites, Pharmacodynamics and Pharmacokinetics of Tamoxifen in Rats and Mice Compared to Breast Cancer Patient. Drug Metabolism Disposition: Biological Fate of Chemicals, 19, 36-43.
[55]  RxList (2008) Nolvadex. Clinical Pharmacology.
http://www.rxlist.com/nolvadex-drug/clinical-pharmacology.htm
[56]  National Cancer Institute (2014) Targeted Cancer Therapies.
http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
[57]  Eniu, A., Carlson, R.W., Aziz, Z., Bines, J., Hortobágyi, G.N., Bese, N.S., Love, R.R., Vikram, B., Kurkure, A., Anderson, B.O. and for the Global Summit Treatment and Allocation of Resources Panel (2006) Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources. The Breast Journal, 12, S38-S53.
http://dx.doi.org/10.1111/j.1075-122X.2006.00202.x
[58]  BMJ Best Practice (2015) Primary Invasive Breast Cancer Treatment-Step-By-Step.
http://bestpractice.bmj.com/best-practice/monograph/716/treatment/step-by-step.html
[59]  Wapnir, I.L., Dignam, J.J., Fisher, B., Mamounas, E.P., Anderson, S.J., Julian, T.B., Land, S.R., Margolese, R.G., Swain, S.M., Costantino, J.P. and Wolmark, N. (2011) Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences after Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. Journal of the National Cancer Institute, 103, 478-488.
http://dx.doi.org/10.1093/jnci/djr027

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133